The estimated Net Worth of Carole Ben Maimon is at least $33.2 Thousand dollars as of 30 May 2019. Carole Maimon owns over 10,000 units of Teligent Inc stock worth over $2,720 and over the last 8 years he sold TLGT stock worth over $0. In addition, he makes $30,444 as Independent Director at Teligent Inc.
Sign up
Carole Maimon TLGT stock SEC Form 4 insiders trading
Carole has made over 2 trades of the Teligent Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of TLGT stock worth $5,900 on 30 May 2019.
The largest trade he's ever made was buying 10,000 units of Teligent Inc stock on 30 May 2019 worth over $5,900. On average, Carole trades about 1,250 units every 47 days since 2016. As of 30 May 2019 he still owns at least 16,000 units of Teligent Inc stock.
You can see the complete history of Carole Maimon stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Carole Ben-Maimon biography
Dr. Carole S. Ben-Maimon is an Independent Director of the Company. Dr. Ben-Maimon has served as a member of our Board of Directors since March 2016. Dr. Ben-Maimon is currently a director, President and Chief Executive Officer of Larimar Therapeutics, Inc. (formerly Zafgen, Inc.), which completed a business combination with Chondrial Therapeutics, Inc., effective May 28, 2020, with Chondrial surviving as a wholly owned subsidiary of Larimar. Larimar Therapeutics, Inc. focuses on developing therapies for complex rare diseases, specifically Friedreich's Ataxia. Prior to the consummation of the merger and from December 2016, Dr. Ben-Maimon served as Chondrial Therapeutics, Inc.’s President, Chief Executive Officer and a member of its Board. Prior thereto and from 2014 to 2016 Dr. Ben-Maimon served as a consultant at CSGB Consulting, LLC. From September 2011 to November 2014, Dr. Ben-Maimon served as President of the generic products division of Impax Laboratories, Inc. Prior to that, she served as Senior Vice President, Corporate Strategy, at Qualitest Pharmaceuticals, Inc. from July 2009 to July 2010. Prior to her role at Qualitest, she served as Founder, President and Chief Executive Officer and director of Alita Pharmaceuticals, Inc., an early stage, privately held specialty pharmaceutical company, from September 2006 to June 2009. Dr. Ben-Maimon also held executive positions with and served as a member of the board with Barr Pharmaceuticals from 2001 to 2006, including as President and Chief Operating Officer of Duramed Research, Inc. (a wholly-owned subsidiary of Barr Pharmaceuticals Inc.).
What is the salary of Carole Maimon?
As the Independent Director of Teligent Inc, the total compensation of Carole Maimon at Teligent Inc is $30,444. There are 3 executives at Teligent Inc getting paid more, with John Celentano having the highest compensation of $36,053.
How old is Carole Maimon?
Carole Maimon is 61, he's been the Independent Director of Teligent Inc since 2016. There are 3 older and 2 younger executives at Teligent Inc. The oldest executive at Teligent Inc is Steven Koehler, 69, who is the Independent Director.
What's Carole Maimon's mailing address?
Carole's mailing address filed with the SEC is C/O TELIGENT, INC., 105 LINCOLN AVENUE, BUENA, NJ, 08310.
Insiders trading at Teligent Inc
Over the last 9 years, insiders at Teligent Inc have traded over $1,419,503 worth of Teligent Inc stock and bought 245,910 units worth $400,963 . The most active insiders traders include James C Gale, Sciences Opportunities Fund..., and John E Celentano. On average, Teligent Inc executives and independent directors trade stock every 89 days with the average trade being worth of $8,816. The most recent stock trade was executed by Philip K Yachmetz on 16 July 2021, trading 7,835 units of TLGT stock currently worth $1,332.
What does Teligent Inc do?
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market.
What does Teligent Inc's logo look like?
Complete history of Carole Maimon stock trades at Teligent Inc
Teligent Inc executives and stock owners
Teligent Inc executives and other stock owners filed with the SEC include:
-
John Celentano,
Chairman of the Board -
Steven Koehler,
Independent Director -
Bhaskar Chaudhuri,
Independent Director -
Carole Ben-Maimon,
Independent Director -
Thomas Sabatino,
Independent Director -
Philip Yachmetz,
Chief Legal Officer, Corporate Secretary -
Timothy Sawyer,
President, Chief Executive Officer, Director -
Martin Wilson,
General Counsel -
Stephen Richardson,
Chief Scientific Officer -
Jenniffer Collins,
CFO -
Narendra N Borkar,
Director -
Sciences Opportunities Fund...,
-
James C Gale,
Director -
Jason Grenfell Gardner,
President & CEO -
Damian Finio,
CFO -
Paolantonio Ernest Robert De,
Chief Financial Officer -
William S Marth,
Director -
R Carter Pate,
Director